Chemotherapy Instead of Hormone Therapy May Be Preferred For Some Castration-Resistant Prostate Cancer Patients

Chemotherapy Instead of Hormone Therapy May Be Preferred For Some Castration-Resistant Prostate Cancer Patients
Researchers from Johns Hopkins University’s Kimmel Cancer Center and James Buchanan Brady Urological Institute have recently released data showing that men with advanced prostate cancer (PC) and detectable levels of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy equally as men who lack AR-V7.  The study, entitled, “Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer,” was published in the latest edition of JAMA Oncology. Metastatic Castration-Resistant Prostate Cancer Metastatic castration-resistant prostate cancer (MCRPC) occurs when the cancer has spread to other parts of the body, and this growth and spread has continued even after drugs or other treatments to lower the amount of male sex hormones are being administered to manage the disease. Male sex hormones, known as androgens, are often the driving force behind prostate cancer growth, as such, a common treatment option for PC is to lower androgen levels in a man’s body. This can be accomplished by surgically removing the testicles or with drugs that stop the testicles from making androgens. This type of treatment is called hormone therapy or androgen-deprivation therapy. The Study In this small clinical trial of 37 MCRPC patients, researchers compared the levels of AR-V7 in patient's blood who had received either docetaxel or cabazitaxel, two chemotherapy drugs. The results showed that of the 17 patients who had detectable levels of AR-V7, there was no statistical differences in how much their PSA levels (markers for prostate cancer) declined, how long it took for their cancers to progress or their overall survival. Another important finding was that 7 of the 17 men in the trial who
Subscribe or to access all post and page content.